

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Akerman et al.

Confirmation No.: 6643

Serial No.: 10/591,214

Group Art Unit No.: 1625

Filed: August 28, 2006

Examiner: Davis, Zinna Northington

For: COMPOUNDS, PHARMACEUTICAL
COMPOSITIONS AND METHODS FOR USE IN
TREATING METABOLIC DISORDERS

Docket No.: A-988-US-PCT

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner Davis:

This is in reply to an Office Action mailed on September 4, 2009, imposing a restriction requirement in the above-captioned patent application. The shortened one-month statutory period for response to the Office Action expires on October 4, 2009. Accordingly, Applicants believe that this response is timely filed.

Applicants believe that no fees are due for this filing. However, should any fees be due, the Patent Office is hereby authorized to charge any additional fees required for this filing or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

In response to the restriction requirement, Applicants provisionally elect the claims, compounds, and compositions of Group I (claims 1-40) for examination without traverse. Applicants further elect the compound of Example 10.13, to begin prosecution.

Remarks begin on page 2 of this document.

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

September 21, 2009
Date

Jacqui Favar
Name